Resource Type

Journal Article 7

Year

2022 1

2016 1

2015 1

2010 1

2009 1

2007 1

Keywords

FAK6/7 1

IRF4 1

IRF8 1

Ki-67 1

PC-cell-derived growth factor 1

SRRM4 1

additional existence 1

available 1

breast 1

breast neoplasms 1

carcinoma 1

clinical markers 1

clinicopathological characteristic 1

diagnosis 1

essential thrombocythemia 1

hydroxyurea 1

intraductal papillary 1

liver metastasis 1

myeloproliferative neoplasms 1

necessitate 1

open ︾

Search scope:

排序： Display mode:

IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 403-415 doi: 10.1007/s11684-021-0858-1

Abstract: The morbidity and mortality of myeloproliferative neoplasms (MPNs) are primarily caused by arterial and

Keywords： myeloproliferative neoplasms     IRF4     IRF8     hydroxyurea     essential thrombocythemia    

HTML PDF Collect

Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological

Yugang Cheng,Hanxiang Zhan,Lei Wang,Jianwei Xu,Guangyong Zhang,Zongli Zhang,Sanyuan Hu

Frontiers of Medicine 2016, Volume 10, Issue 4,   Pages 444-450 doi: 10.1007/s11684-016-0471-x

Abstract:

The incidence rate of pancreatic neuroendocrine neoplasms (pNENs) has increased rapidly in recent

Keywords： pancreatic neuroendocrine neoplasms     clinicopathological characteristic     Ki-67     liver metastasis     outcomes    

HTML PDF Collect

The clinicopathologic features of intraductal papillary mucinous neoplasms of the pancreas

QIN Xinyu, LIU Fenglin

Frontiers of Medicine 2007, Volume 1, Issue 2,   Pages 121-125 doi: 10.1007/s11684-007-0023-5

Abstract: Since first described in 1982, intraductal papillary mucinous neoplasm (IPMN) has been the preferred term to describe the proliferation of the pancreatic ductal epithelium. It is totally different from pancreatic carcinoma in epi demiology, histology, pathology and prognosis. According to the site of involvement, IPMNs are classified into three categories, i.e. main duct type, branch duct type, and combined type. Most branch duct IPMNs are benign, whereas the other two types are often malignant. A large branch duct IPMN and marked dilation of the main pancreatic duct indicate the presence of adenoma at least. The additional existence of large mural nodules increases the possibility of malignancy in all types. The prognosis is more favorable after complete resection of benign and non-invasive malignant IPMNs. Malignant IPMNs that become more aggressive after parenchymal invasion necessitate adequate lymph node dissection. On the other hand, asymptomatic branch duct IPMNs without mural nodules can be observed without the need for resection for a considerable period of time. Our review addresses available data, current understanding, controversy, and future directions about IPMNs.

Keywords： available     additional existence     necessitate     intraductal papillary     non-invasive    

HTML PDF Collect

Small cell carcinoma of the urinary bladder without gross hematuria: a case report

Wanqiu Huang,Yang Luan,Lu Jin,Tao Wang,Ruibao Chen,Zheng Liu,Zhiqiang Chen,Ruzhu Lan

Frontiers of Medicine 2015, Volume 9, Issue 3,   Pages 384-387 doi: 10.1007/s11684-015-0405-z

Abstract:

Small cell carcinoma of the urinary bladder (SCCB) is a rare and aggressive form of bladder cancer with poor prognosis. Hematuria is the main symptom of this malignancy, and most patients have a history of smoking. The disease incidence of malignant bladder tumors in China is approximately 0.74%. Early and accurate diagnosis of SCCB can ensure timely and appropriate treatment of this malignant disease. Oncologic surgery is the standard treatment; however, it may not be a curative approach. Chemotherapy and/or radiotherapy should be performed following surgical removal. This case report describes a patient with a single neoplasm diagnosed as SCCB that arose because of recurrence of bladder cancer after bladder tumor resection. In contrast to previously reported cases, this patient had no gross hematuria and no history of smoking.

Keywords： carcinoma     small cell     urinary bladder neoplasms     diagnosis    

HTML PDF Collect

High frequency of alternative splicing variants of the oncogene in neuroendocrine tumors of the pancreas and breast

Frontiers of Medicine   Pages 907-923 doi: 10.1007/s11684-023-1009-7

Abstract: The characteristic genetic abnormality of neuroendocrine neoplasms (NENs), a heterogeneous group of tumors/strong>) of 45 pancreatic NENs, 19 (47.5%) of 40 pancreatic solid pseudopapillary neoplasms

Keywords： FAK6/7     SRRM4     neuroendocrine neoplasms     pancreas     breast    

HTML PDF Collect

Expression of PC-cell-derived growth factor in breast cancer

Haiping SONG MD, Lan SHI MD, Chunping LIU MD, Tao HUANG MD,

Frontiers of Medicine 2009, Volume 3, Issue 4,   Pages 426-430 doi: 10.1007/s11684-009-0085-7

Abstract: This study is mainly aimed at evaluating the expression of PC-cell-derived growth factor (PCDGF) in breast cancer and breast adenofibroma, and to compare with other commonly used clinical pathological indices, then to investigate the diagnostic and targeted therapeutic purpose of PCDGF in breast cancer tissue. In this study, we detected the expression of PCDGF, p53 and CerbB-2 in breast cancer tissue and the expression of PCDGF in breast adenofibroma tissue by immunohistochemical method, and analyzed the relationship between them. We found that PCDGF was expressed in most breast cancer tissue, but was not in breast adenofibroma tissue, and the expression of PCDGF was related with the tumor’s pathological category and the expression of estrogen receptor (ER) and progesterone receptor (PR) and p53, but there was no statistical dependability between PCDGF and cerbB-2. From this study, we predict that PCDGF may serve as a marker in the secondary diagnosis of breast cancer, and may participate in the generation and differentiation of breast cancer cells, and become an effective target of therapy for breast cancer.

Keywords： PC-cell-derived growth factor     breast neoplasms     clinical markers    

HTML PDF Collect

Influence of the adjuvant therapy on the survival of patients with stage II pancreatic carcinoma

Xi-Yan WANG, Hai-Jun LI, Dong YAN, Hao WEN, Shu-Yong PENG,

Frontiers of Medicine 2010, Volume 4, Issue 4,   Pages 430-435 doi: 10.1007/s11684-010-0700-7

Abstract: This study aimed to investigate the effect of adjuvant therapy on the treatment of stage II pancreatic carcinomas. The clinical data of 139 cases of stage II pancreatic carcinoma were analyzed retrospectively. The overall 1-, 3-, and 5-year cumulative survival rates of 139 patients were 40%, 6%, and 3%, respectively, and the median survival time (MST) was 279 days. The MST was 399 days for those with adjuvant therapy, 210 days for those without adjuvant therapy, 390 days for the radical resection group, 270 days for the bypass operation and laparotomy group, and 132 days for the nonsurgical group. The adjuvant therapy could not prolong the survival time and decrease the liver metastasis rate of the patients with stage II carcinoma significantly in radical resection group (>0.05). In the bypass operation and laparotomy group and nonsurgical group, the adjuvant therapy could improve the survival of the patients significantly (<0.05); however, the survival rate was not significantly different among systemic venous chemotherapy, radiation therapy, interventional therapy, and combination therapy (>0.05); or between gemcitabine (GEM) regimen and 5-fluorouracil regimen (>0.05); or between GEM monotherapy and GEM combined with platinum/capecitabine (>0.05). The proper adjuvant therapy can be suggested according to the general condition of the patients after radical resection for stage II pancreatic carcinoma. Chemotherapy combined with radiation should be applied actively for the patients whose cancerous tissues were not radically resected. The clinical efficacy of GEM combined with platinum/capecitabine is relatively better than GEM.

Keywords： pancreatic neoplasms     neoadjuvant therapy     survival    

HTML PDF Collect

Title Author Date Type Operation

IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia

Journal Article

Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological

Yugang Cheng,Hanxiang Zhan,Lei Wang,Jianwei Xu,Guangyong Zhang,Zongli Zhang,Sanyuan Hu

Journal Article

The clinicopathologic features of intraductal papillary mucinous neoplasms of the pancreas

QIN Xinyu, LIU Fenglin

Journal Article

Small cell carcinoma of the urinary bladder without gross hematuria: a case report

Wanqiu Huang,Yang Luan,Lu Jin,Tao Wang,Ruibao Chen,Zheng Liu,Zhiqiang Chen,Ruzhu Lan

Journal Article

High frequency of alternative splicing variants of the oncogene in neuroendocrine tumors of the pancreas and breast

Journal Article

Expression of PC-cell-derived growth factor in breast cancer

Haiping SONG MD, Lan SHI MD, Chunping LIU MD, Tao HUANG MD,

Journal Article

Influence of the adjuvant therapy on the survival of patients with stage II pancreatic carcinoma

Xi-Yan WANG, Hai-Jun LI, Dong YAN, Hao WEN, Shu-Yong PENG,

Journal Article